全文获取类型
收费全文 | 73703篇 |
免费 | 2886篇 |
国内免费 | 786篇 |
专业分类
耳鼻咽喉 | 566篇 |
儿科学 | 884篇 |
妇产科学 | 870篇 |
基础医学 | 7611篇 |
口腔科学 | 3626篇 |
临床医学 | 5600篇 |
内科学 | 13563篇 |
皮肤病学 | 1380篇 |
神经病学 | 5724篇 |
特种医学 | 1730篇 |
外国民族医学 | 2篇 |
外科学 | 13993篇 |
综合类 | 3844篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 5689篇 |
眼科学 | 1172篇 |
药学 | 4205篇 |
15篇 | |
中国医学 | 2415篇 |
肿瘤学 | 4480篇 |
出版年
2023年 | 717篇 |
2022年 | 1299篇 |
2021年 | 2502篇 |
2020年 | 1643篇 |
2019年 | 5511篇 |
2018年 | 5807篇 |
2017年 | 3718篇 |
2016年 | 1282篇 |
2015年 | 1296篇 |
2014年 | 2340篇 |
2013年 | 2364篇 |
2012年 | 1705篇 |
2011年 | 2062篇 |
2010年 | 1648篇 |
2009年 | 1516篇 |
2008年 | 1543篇 |
2007年 | 1446篇 |
2006年 | 1244篇 |
2005年 | 1006篇 |
2004年 | 849篇 |
2003年 | 802篇 |
2002年 | 591篇 |
2001年 | 644篇 |
2000年 | 518篇 |
1999年 | 510篇 |
1998年 | 305篇 |
1997年 | 299篇 |
1996年 | 243篇 |
1995年 | 238篇 |
1994年 | 199篇 |
1993年 | 185篇 |
1992年 | 179篇 |
1991年 | 164篇 |
1990年 | 104篇 |
1989年 | 136篇 |
1988年 | 105篇 |
1987年 | 120篇 |
1985年 | 2860篇 |
1984年 | 3410篇 |
1983年 | 2892篇 |
1982年 | 3350篇 |
1981年 | 3040篇 |
1980年 | 2536篇 |
1979年 | 2506篇 |
1978年 | 2067篇 |
1977年 | 1536篇 |
1976年 | 1995篇 |
1975年 | 1513篇 |
1974年 | 1324篇 |
1973年 | 1274篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
目的 探讨食管癌高、低发区食管鳞癌患者的生存状况及其影响因素。方法 收集38 741例经病理学证实为食管鳞癌患者的资料,其中,高发区患者23 273例(60.1%),低发区15 468例(39.9%)。所有患者均行食管癌根治术。运用卡方检验分析不同临床病理特征患者的组间差异,Kaplan-Meier法绘制不同临床病理特征患者的生存曲线并用Log rank进行检验。多因素Cox比例风险回归模型法分析影响生存的主要因素。结果 低发区男性患者所占比例高于高发区(P<0.001),低发区诊断年龄≥50岁食管癌患者所占比例高于高发区(P<0.001)。高发区食管鳞癌患者的整体生存优于低发区患者(P<0.001)。Cox比例风险回归模型综合分析结果表明:高低发区、性别、确诊年龄、肿瘤部位、分化程度、TNM分期和肿瘤家族史均是影响食管鳞癌患者生存的独立因素。结论 高发区食管鳞癌患者整体生存优于低发区;低发区是食管鳞癌患者预后差的独立危险因素。 相似文献
12.
目的:调查心脏瓣膜置换术后患者的出院准备度现状,并分析其影响因素。方法:于2018年9月至2019年3月用一般资料、出院准备度量表、出院指导质量量表对139例瓣膜置换术后患者进行调查。结果:心脏瓣膜置换术后患者的出院准备度总分为(89.51±8.53)分,与出院指导质量呈正相关;多元回归分析显示,主要照顾者、婚姻状况、工作状态、服药种类、出院指导质量为出院准备度影响因素。结论:心脏瓣膜置换术后患者的出院准备度有待提高,患者感知的个人状态得分不理想;护士应鼓励患者配合进行早期康复,强化出院指导,采取有效措施提供康复信息,满足患者及其家属需求,提高出院准备度。 相似文献
13.
14.
Sevim Turanli Nazan Bozdogan Hakan Mersin Ugur Berberoglu 《The Indian journal of surgery》2015,77(6):489-494
Helicobacter pylori has been associated with diverse pathologies of varying severity. We investigated the H. pylori infection status and its association with the pathologic features and clinical outcomes in stage III gastric cancer patients treated with adjuvant therapy after curative resection. Between 2004 and 2009, the records of 76 consecutive patients were retrospectively reviewed. H. pylori infection was confirmed by examination of pathological specimen. The relationship between H. pylori and the clinicopathological features was analyzed by Fisher exact test, Student’s t test, and Kaplan-Meier method. Of the 76 patients, 16 patients (21.1 %) were confirmed for H. pylori infection. The median age was 59 years. Twenty-three patients received chemotherapy and remainder received chemoradiotherapy. H. pylori status did not correlate with the clinicopathologic features. It was greater in non-neoplastic tissue than the tumor tissue (21.1 vs 7.9 %). Median follow-up was 21 months. During this period, 88.2 % patients had experienced tumor recurrence, and 85.5 % patients had died. Recurrence was observed in 87.5 % patients and in 88.3 % patients in H. pylori-positive and H. pylori-negative patients, respectively (P = 0.92). Disease-free survival was 28.4 ± 7.9 months and overall survival was 31.5 ± 7.4 months in H. pylori-positive patients compared with 28.3 ± 3.7 and 33.2 ± 3.4 months, respectively, in H. pylori-negative patients. H. pylori infection status did not have effect on the overall or disease-free survival (p = 0.85 and P = 0.86), respectively. H. pylori status might not be useful as a prognostic and predictive factor for clinical outcomes. 相似文献
15.
16.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献
17.
18.
19.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):25-34
PurposeTo investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A–B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses.ResultsThe median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6–11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1–3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9–23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6–26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2–7.2), and progression-free survival was 5.7 months (95% CI, 4.3–7.1).ConclusionsRadioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy. 相似文献